Isoniazid resistance and death in patients with tuberculous meningitis: Retrospective cohort study

BMJ (Online)

Volumn 341, Issue 7773, 2010, Pages 596-

  Vinnard, Christopher ^a   Winston, Carla A ^b   Wileyto, E Paul ^a   MacGregor, Rob Roy ^a   Bisson, Gregory P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CEREBROSPINAL FLUID; CHILD; COHORT ANALYSIS; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TUBERCULOUS MENINGITIS;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; ISONIAZID; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MENINGEAL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 77956813816     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c4451     Document Type: Article

References (34)

1. Silber E, Sonnenberg P, Ho KC, Koornhof HJ, Eintracht S, Morris L, et al. Meningitis in a community with a high prevalence of tuberculosis and HIV infection. J Neurol Sci 1999;162:20-6. (Pubitemid 29064113)
2. Bergemann A, Karstaedt AS. The spectrum of meningitis in a population with high prevalence of HIV disease. QJM 1996;89:499-504. (Pubitemid 26245389)
3. Thwaites GE, Tran TH. Tuberculous meningitis: many questions, too few answers. Lancet Neurol 2005;4:160-70.
4. Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculousmeningitis. Am Rev Respir Dis 1993;148:650-5.
5. Shin SG, Roh JK, Lee NS, Shin JG, Jang IJ, Park CW, et al. Kinetics of isoniazid transfer into cerebrospinal fluid in patients with tuberculous meningitis. J Korean Med Sci 1990;5:39-45. (Pubitemid 20373443)
6. Girgis NI, Yassin MW, Laughlin LW, Edman DC, Farid Z, Watten RH. Rifampicin in the treatment of tuberculous meningitis. J Trop Med Hyg 1978;81:246-7.
7. Girgis NI, Yassin MW, Sippel JE, Sorensen K, Hassan A, Miner WF, et al. The value of ethambutol in the treatment of tuberculous meningitis. J Trop Med Hyg 1976;79:14-7.
8. Nau R, Prange HW, Menck S, Kolenda H, Visser K, Seydel JK. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother 1992;29:719-24.
9. Ellard GA, Humphries MJ, Gabriel M, Teoh R. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. BMJ 1987;294:284-5. (Pubitemid 17006325)
10. Phuapradit P, Supmonchai K, Kaojarern S, Mokkhavesa C. The blood/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis. J Neurol Neurosurg Psychiatry 1990;53:81-2. (Pubitemid 20034370)
11. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003;167:1348-54. (Pubitemid 36609718)
12. Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW, et al. Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther 2003;1:141-55. (Pubitemid 38735735)
13. Mitchison DA, Nunn AJ. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 1986;133:423-30.
14. Treatment of tuberculosis. MMWR Recomm Rep 2003;52:1-77.
15. Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev 2008;21:243-61. (Pubitemid 351555506)
16. Nau R, Sorgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 1998;35:223-46. (Pubitemid 28430036)
17. Thwaites GE, Lan NT, Dung NH, Quy HT, Oanh DT, Thoa NT, et al. Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis 2005;192:79-88.
18. Trends in tuberculosis - United States, 2008. MMWR Morb Mortal Wkly Rep 2009;58:249-53.
19. Curtis AB, McCray E, McKenna M, Onorato IM. Completeness and timeliness of tuberculosis case reporting: a multistate study. Am J Prev Med 2001;20:108-12. (Pubitemid 32109228)
20. Little R, Rubin D. Statistical analysis with missing data. Wiley; 1987.
21. Patel VB, Padayatchi N, Bhigjee AI, Allen J, Bhagwan B, Moodley AA, et al. Multidrug-resistant tuberculous meningitis in KwaZulu-Natal, South Africa. Clin Infect Dis 2004;38:851-6.
22. Thwaites GE, Caws M, Chau TT, Dung NT, Campbell JI, Phu NH, et al. Comparison of conventional bacteriology with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculous chemotherapy. J Clin Microbiol 2004;42:996-1002.
23. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1987;136:1339-42.
24. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008;149:123-34. (Pubitemid 352008599)
25. Palomino JC. Molecular detection, identification and drug resistance detection in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 2009;56:103-11.
26. Kalita J, Misra UK, Ranjan P. Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis. Eur J Neurol 2007;14:33-7. (Pubitemid 46088033)
27. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004;351:1741-51.
28. Arnold AM, Kronmal RA. Multiple imputation of baseline data in the cardiovascular health study. Am J Epidemiol 2003;157:74-84.
29. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006;59:1087-91. (Pubitemid 44374314)
30. Van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. J Clin Epidemiol 2006;59:1102-9. (Pubitemid 44374315)
31. Hoopes AJ, Kammerer JS, Harrington TA, Ijaz K, Armstrong LR. Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. Arch Intern Med 2008;168:1984-92.
32. French CE, Glynn JR, Kruijshaar ME, Ditah IC, Delpech V, Abubakar I. The association between HIV and antituberculosis drug resistance. Eur Respir J 2008;32:718-25.
33. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-54.
34. Thwaites G, Fisher M, Hemingway C, Scott G, Solomon T, Innes J. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009;59:167-87.